Rafael (NYSE:RFL) Trading 4.6% Higher – What’s Next?

Rafael Holdings, Inc. (NYSE:RFL) rose 4.6% during mid-day trading on Thursday . The stock traded as high as $1.94 and last traded at $1.8940. Approximately 79,259 shares changed hands during mid-day trading, a decline of 17% from the average session volume of 95,924 shares. The stock had previously closed at $1.81.

Wall Street Analysts Forecast Growth

Several research firms have commented on RFL. Wall Street Zen raised shares of Rafael to a “hold” rating in a research report on Saturday, July 25th. Weiss Ratings raised Rafael from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, May 28th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has an average rating of “Sell”.

Rafael Price Performance

The firm has a market capitalization of $112.32 million, a PE ratio of -3.18 and a beta of 0.33. The company’s fifty day simple moving average is $2.35 and its 200 day simple moving average is $1.69.

Institutional Trading of Rafael

Hedge funds have recently made changes to their positions in the business. Geode Capital Management LLC increased its stake in Rafael by 72.9% during the second quarter. Geode Capital Management LLC now owns 451,139 shares of the company’s stock worth $781,000 after acquiring an additional 190,179 shares during the last quarter. Marshall Wace LLP purchased a new position in shares of Rafael in the 2nd quarter worth approximately $50,000. Cable Car Capital LP purchased a new position in shares of Rafael in the 2nd quarter worth approximately $173,000. Vanguard Group Inc. increased its position in shares of Rafael by 10.5% during the 3rd quarter. Vanguard Group Inc. now owns 1,394,726 shares of the company’s stock valued at $1,897,000 after purchasing an additional 133,024 shares during the last quarter. Finally, Citadel Advisors LLC raised its holdings in Rafael by 132.3% during the 3rd quarter. Citadel Advisors LLC now owns 72,584 shares of the company’s stock valued at $99,000 after buying an additional 41,335 shares during the period. 11.30% of the stock is currently owned by hedge funds and other institutional investors.

About Rafael

Rafael Holdings, Inc primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), currently under Phase III clinical study for the treatment of metastatic pancreatic cancer and acute myeloid leukemia.